Leukemia
Back to Oncology/Cancer Clinical Trials Main PageCPMC Cancer Services
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 | Cytogenetic Studies in Leukemia Patients (Ancillary Cytogenetic Study (registry) SWOG 9007 Visit this study on ClinicalTrials.gov. | Subjects with Leukemia | Open |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 | Leukemia Centralized Reference Laboratory and Tissue Repository (registry) SWOG 9910 Visit this study on ClinicalTrials.gov. | Subjects with Leukemia or Myelodysplasia | Open |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 | A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) Induction Therapy vs. Standard Induction with Daunomycin and cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated DeNovo Acute Myeloid Leukemia (AML). SWOG S0106 Visit this study on ClinicalTrials.gov. | Subjects under age 61 with previously untreated DeNovo Acute Myeloid Leukemia | Closed to Enrollment |
updated: 11/13/09
Back to top